personally, I think this is an opportunity to accumulate the stock.
ACR have de-risked Axiron. WIll have $140m+ in the bank, with sales through 2011.
Don't forget Eli Lilly are a well oiled machine. Watch them run getting it to physicians.
While the product application is obviously very important, you can't discount the importance of the quality of the distributor.
ACR shareholders will enjoy a great 2011. There is $4 written all over this stock over the next 6 months with a special divi on top.
get ready for blastoff, page-17
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
